Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial
JMIR Research Protocols · 2025
DOI: 10.2196/72597 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JMIR Research Protocols, 2025. Verfasst von Yongle Zhan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China (Hong Kong). Hauptthemen laut MEDLINE: Circulating Tumor DNA, Carcinoma, Transitional Cell. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Health and Medical Research Fund.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Urothelial carcinoma is one of the most commonly diagnosed cancers worldwide, with a poor 5-year survival rate. As genomics is the backbone of the precision medicine paradigm, the genetic signature in circulating tumor DNA (ctDNA) is emerging as a pivotal biomarker for detecting early-stage cancer and molecular residual disease (MRD).
Objective
We aim to evaluate the feasibility and preliminary effects of a ctDNA-based sequencing approach for detecting MRD and guiding adjuvant chemotherapy in postoperative urothelial carcinomas.
Methods
We will perform a stratified 2-arm pilot randomized controlled trial in 2 tertiary hospitals in Hong Kong, involving patients with urothelial carcinomas (pT2-4a N0-2 M0) undergoing radical resection. We plan to recruit 20 patients and determine stratification according to their MRD status before randomization. Patients in each stratum (MRD-positive and MRD-negative groups) will be randomly allocated to either a 4-cycle gemcitabine plus cisplatin chemotherapy arm or a standard management arm in a 1:1 ratio. ctDNA MRD will be tested using a personalized next-generation sequencing panel, which is designed based on the individual’s whole exome sequencing results from the operation specimen. The primary outcome is the feasibility of this trial (ie, recruitment, retention, adherence, and completeness). The secondary outcome is treatment-related adverse events. Exploratory outcomes include radiographic disease-free survival, cancer-specific survival, overall survival, ctDNA clearance in patients with ctDNA MRD-positive status, quality of life, fear of cancer recurrence, and cost-effectiveness. Benchmarks for feasibility evaluation are set as (1) ≥20% recruitment response rate, (2) ≤20% loss to follow-up or withdrawal, (3) ≥80% intervention adherence, and (4) ≤20% missing value rate. Each benchmark will be assigned one score, and a total score of 4, 2 to 3, and 0 to 1 will be deemed high, medium, and low feasibility, respectively. Safety evaluations will be presented as numbers and proportions of the adverse events. ANOVA and the Kruskal-Wallis test will be used for continuous outcome variables, whereas the chi-square test and the Fisher exact test will be used for categorical outcome variables. Hazard ratios will be calculated to compare the preliminary treatment effect of the gemcitabine plus cisplatin arm against the standard management arm on survival within each MRD group.
Results
This project was funded in February 2024. Patient recruitment started on May 2, 2024. Recruitment and data collection for the trial are ongoing. Data analysis will be performed in mid-2025 and the results of this study are expected to be published in late 2025.
Conclusions
Genetic signature in ctDNA is informative for personalized management of postoperative urothelial carcinomas, including personalized treatment and early detection of disease progression. Trial Registration ClinicalTrials.gov NCT06257017; https://clinicaltrials.gov/study/NCT06257017 International Registered Report Identifier (IRRID) DERR1-10.2196/72597
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China (Hong Kong).
- Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China (Hong Kong).
- Division of Urology, Department of Surgery, Queen Mary Hospital, Hong Kong, China (Hong Kong).
- Department of Medicine, Queen Mary Hospital, Hong Kong, China (Hong Kong).
ORCID-Profile: Yongle Zhan, Xiaohao Ruan, Yishuo Wu, Tsun Tsun Stacia Chun, Chi Yao, Ruofan Shi, Jiacheng Liu, Salida Ali, Ruochen Ma, Da Huang, Yi Gao, Ying Xu, Lu Chen, Qijun Du, Ada Tsui-Lin Ng, Cho Wing Bryan Li, Danfeng Xu, Rong Na
Förderung
- Health and Medical Research Fund
Zitieren
APA
Zhan, Y., Ruan, X., Wu, Y., Chun, T. T. S., Yao, C., Shi, R., Liu, J., Ali, S., Ma, R., Huang, D., Gao, Y., Xu, Y., Chen, L., Du, Q., Ng, A. T., Li, C. W. B., Xu, D., & Na, R. (2025). Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols. https://doi.org/10.2196/72597
Vancouver
Zhan Y, Ruan X, Wu Y, Chun TTS, Yao C, Shi R, et al. Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols. 2025. doi:10.2196/72597
BibTeX
@article{Zhan2025,
author = {Zhan, Yongle and Ruan, Xiaohao and Wu, Yishuo and Chun, Tsun Tsun Stacia and Yao, Chi and Shi, Ruofan and Liu, Jiacheng and Ali, Salida and Ma, Ruochen and Huang, Da and Gao, Yi and Xu, Ying and Chen, Lu and Du, Qijun and Ng, Ada Tsui-Lin and Li, Cho Wing Bryan and Xu, Danfeng and Na, Rong},
title = {Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial},
journal = {JMIR Research Protocols},
year = {2025},
doi = {10.2196/72597}
}
EUVIMED